This clinical trial is focused on studying acute lymphoblastic leukemia (ALL), a type of cancer that affects the blood and bone marrow, in children and adolescents. The treatment being tested in this study is called pegaspargase, which is a medication used to treat ALL. Pegaspargase is given as an injection and works by breaking down a substance in the body that cancer cells need to grow.
The purpose of the study is to evaluate how effective and safe different schedules of pegaspargase are for patients aged 12 months to less than 18 years who have been newly diagnosed with standard or medium-risk ALL. The study will also look at the effects of a more intense treatment schedule for those with high or very high-risk ALL. Participants will receive pegaspargase as part of their treatment plan, and the study will monitor how well the medication works and any side effects that may occur.
Throughout the study, researchers will assess the activity of pegaspargase in the body and monitor for any severe side effects, such as issues with the pancreas or allergic reactions. The study will also explore the occurrence of rare subtypes of ALL and their impact on treatment outcomes. The trial aims to provide valuable information on the best ways to use pegaspargase in treating ALL in young patients.
France 
